查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1594060

代謝失調治療藥物市場：依疾病類型、產品類型分類 - 全球預測 2025-2030

Metabolic Disorders Therapeutics Market by Disease Type (Diabetes, Hypercholesterolemia, Lysosomal Storage Disease), Product (Globoid Leukodystrophy, Hepatic Encephalopathy, Metachromatic Leukodystrophy) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年代謝紊亂藥物市值為614.1億美元，預計2024年將達667.8億美元，複合年成長率為8.82%，到2030年將達到1110.4億美元。

代謝紊亂藥物市場範圍廣闊，包括以體內代謝異常化學反應為特徵的疾病的治療方法的開拓和應用。這包括糖尿病、高膽固醇症和溶小體貯積等疾病。這項需求是由於生活方式的改變、老化和遺傳傾向等因素導致全世界代謝紊亂的盛行率不斷增加。這些治療劑應用於醫院、診所和居家醫療機構，其中包括低分子化合物和生技藥品在內的藥物是主要的干涉方法。最終用途範圍從兒科到成人患者，治療需求根據疾病階段而有所不同。

主要市場統計
基準年[2023] 614.1億美元
預測年份 [2024] 667.8億美元
預測年份 [2030] 1110.4億美元
複合年成長率（%） 8.82%

市場成長是由生物技術的進步、醫療保健支出的增加和意識的提高所推動的。關鍵的成長要素包括新的治療選擇的出現，例如基因治療和個人化醫療，它們可以提高療效並減少副作用。人口老化和文明病的增加推動了需求。機會在於瞄準新興市場，這些市場的醫療基礎設施改善和經濟成長正在增加醫療服務的覆蓋範圍。公司應專注於加強藥物輸送系統和患者依從性以發展業務。與當地醫療保健提供者和監管機構的合作也將促進這些地區的市場滲透。

然而，市場面臨高昂的研發成本和嚴格的監管要求等限制，阻礙了快速商業化。由於代謝性疾病的複雜性，個人化診斷和治療計劃通常是一個挑戰，增加了開發治療方法所需的成本和時間。此外，專利到期以及與生物相似藥的競爭也是主要問題。

可以透過專注於開發聯合治療和探索提供患者管理工具的數位健康解決方案來推動創新。用於早期檢測和監測代謝異常的生物標記研究可以簡化治療方法並改善結果。該市場競爭激烈，但對於那些能夠克服監管障礙、適應技術進步並在新治療領域領先於患者需求的公司來說充滿了機會。

市場動態：快速發展的代謝疾病治療市場的關鍵市場洞察

供需的動態交互作用正在改變代謝紊亂藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 提高對代謝性疾病治療的認知
    • 不斷成長的人口中各種代謝疾病的盛行率
    • 改善代謝疾病的檢查和診斷
  • 市場限制因素
    • 治療費用上漲且無法報銷
  • 市場機會
    • 增加開發新治療方法的資金
    • 基因療法治療代謝疾病的潛力
  • 市場挑戰
    • 嚴格的政府核准標準和規定

波特五力：駕馭代謝疾病藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解代謝紊亂治療藥物市場的外部影響

外部宏觀環境因素在塑造代謝紊亂藥物市場的動態表現方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解代謝紊亂治療藥物市場的競爭狀況

代謝紊亂藥物市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位基質代謝紊亂治療市場供應商的績效評估

FPNV定位矩陣是評估代謝性疾病藥物市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪代謝紊亂治療市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，代謝紊亂藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 提高對代謝性疾病治療的認知
      • 由於人口成長導致各種代謝疾病的傳播
      • 改善代謝紊亂的測試和診斷
    • 抑制因素
      • 治療費用上漲且無法報銷
    • 機會
      • 增加開發新治療方法的資金
      • 基因療法治療代謝性疾病的可能性
    • 任務
      • 嚴格的政府核准的標準和法規
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章代謝紊亂治療藥物市場：依疾病類型

  • 糖尿病
  • 高膽固醇症
  • 溶小體儲積症
  • 肥胖

第7章代謝紊亂治療藥物市場：依產品

  • 球狀腦白質營養不良
  • 肝性腦病變
  • 異染性腦白質營養不良

第8章北美與南美代謝紊亂治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區代謝失調治療藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲代謝紊亂治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amicus Therapeutics, Inc.
  • Astrazeneca PLC
  • Biocon
  • BioMarin Pharmaceutical Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novo Nordisk A/S
  • Sanofi SA
  • Sigilon Therapeutics, Inc.
Product Code: MRR-0363DFE03688

The Metabolic Disorders Therapeutics Market was valued at USD 61.41 billion in 2023, expected to reach USD 66.78 billion in 2024, and is projected to grow at a CAGR of 8.82%, to USD 111.04 billion by 2030.

The scope of the Metabolic Disorders Therapeutics market is vast, involving the development and application of treatments for diseases characterized by abnormal chemical reactions in the body's metabolism. This includes conditions like diabetes, hypercholesterolemia, and lysosomal storage disorders. Necessity is driven by the increasing prevalence of metabolic disorders globally, spurred by factors such as lifestyle changes, aging populations, and genetic predispositions. These therapeutics find applications in hospitals, clinics, and homecare settings, with pharmaceuticals being the primary mode of intervention, including small molecules and biologics. End-use scope extends to pediatric and adult patients with varied treatment needs depending on disease progression.

KEY MARKET STATISTICS
Base Year [2023] USD 61.41 billion
Estimated Year [2024] USD 66.78 billion
Forecast Year [2030] USD 111.04 billion
CAGR (%) 8.82%

Market growth is being propelled by advancements in biotechnology, rising healthcare expenditure, and increased awareness. Key growth factors include the emergence of novel treatment options like gene therapy and personalized medicine, which offer improved efficacy and reduced side effects. Aging populations and increasing incidence of lifestyle-related disorders are driving demand. Opportunities lie in targeting emerging markets where healthcare infrastructure improvements and growing economies are widening access. Companies should focus on enhancing drug delivery systems and patient compliance for business growth. Partnerships with local healthcare providers and regulatory bodies can also facilitate market penetration in these regions.

However, the market faces limitations including high R&D costs and stringent regulatory requirements, which can hinder quick commercialization. The complexity of metabolic disorders often results in challenging diagnosis and individualized treatment plans, adding to the cost and time involved in therapeutic development. Moreover, patent expirations and competition from biosimilars pose significant challenges.

Innovation can be driven by focusing on developing combination therapies and exploring digital health solutions that provide patient management tools. Research into biomarkers for early detection and monitoring of metabolic disorders could streamline treatment approaches and improve outcomes. The nature of the market is competitive but ripe with opportunities for those that can navigate regulatory hurdles, adapt to technological advancements, and anticipate patient needs in emerging therapeutic areas.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Metabolic Disorders Therapeutics Market

The Metabolic Disorders Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing awareness regarding the treatment of metabolic disorders
    • Prevalence of various metabolic diseases in the growing population
    • Improvements in metabolic disorder testing and diagnosis
  • Market Restraints
    • High cost of therapeutics and lack of reimbursements
  • Market Opportunities
    • Rise in the funding for the development of novel therapeutic approaches
    • Potential of gene therapy for metabolic disorder treatment
  • Market Challenges
    • Strict government approval standards and regulations

Porter's Five Forces: A Strategic Tool for Navigating the Metabolic Disorders Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Metabolic Disorders Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Metabolic Disorders Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Metabolic Disorders Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Metabolic Disorders Therapeutics Market

A detailed market share analysis in the Metabolic Disorders Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Metabolic Disorders Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Metabolic Disorders Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Metabolic Disorders Therapeutics Market

A strategic analysis of the Metabolic Disorders Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Metabolic Disorders Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alexion Pharmaceuticals, Inc., Amicus Therapeutics, Inc., Astrazeneca PLC, Biocon, BioMarin Pharmaceutical Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck KGaA, Novo Nordisk A/S, Sanofi S.A., and Sigilon Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the Metabolic Disorders Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Type, market is studied across Diabetes, Hypercholesterolemia, Lysosomal Storage Disease, and Obesity.
  • Based on Product, market is studied across Globoid Leukodystrophy, Hepatic Encephalopathy, and Metachromatic Leukodystrophy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing awareness regarding the treatment of metabolic disorders
      • 5.1.1.2. Prevalence of various metabolic diseases in the growing population
      • 5.1.1.3. Improvements in metabolic disorder testing and diagnosis
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of therapeutics and lack of reimbursements
    • 5.1.3. Opportunities
      • 5.1.3.1. Rise in the funding for the development of novel therapeutic approaches
      • 5.1.3.2. Potential of gene therapy for metabolic disorder treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Strict government approval standards and regulations
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Metabolic Disorders Therapeutics Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Diabetes
  • 6.3. Hypercholesterolemia
  • 6.4. Lysosomal Storage Disease
  • 6.5. Obesity

7. Metabolic Disorders Therapeutics Market, by Product

  • 7.1. Introduction
  • 7.2. Globoid Leukodystrophy
  • 7.3. Hepatic Encephalopathy
  • 7.4. Metachromatic Leukodystrophy

8. Americas Metabolic Disorders Therapeutics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Metabolic Disorders Therapeutics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Metabolic Disorders Therapeutics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Alexion Pharmaceuticals, Inc.
  • 3. Amicus Therapeutics, Inc.
  • 4. Astrazeneca PLC
  • 5. Biocon
  • 6. BioMarin Pharmaceutical Inc.
  • 7. Eli Lilly and Company
  • 8. F. Hoffmann-La Roche Ltd
  • 9. GlaxoSmithKline PLC
  • 10. Johnson & Johnson Services, Inc.
  • 11. Merck KGaA
  • 12. Novo Nordisk A/S
  • 13. Sanofi S.A.
  • 14. Sigilon Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. METABOLIC DISORDERS THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. METABOLIC DISORDERS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. METABOLIC DISORDERS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. METABOLIC DISORDERS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. METABOLIC DISORDERS THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY LYSOSOMAL STORAGE DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY OBESITY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GLOBOID LEUKODYSTROPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HEPATIC ENCEPHALOPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY METACHROMATIC LEUKODYSTROPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. AUSTRALIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CHINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. INDIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. INDONESIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. JAPAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. MALAYSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. PHILIPPINES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. SINGAPORE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. SOUTH KOREA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. TAIWAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. THAILAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. VIETNAM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. ITALY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. NETHERLANDS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. NIGERIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. NORWAY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. POLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. QATAR METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. RUSSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SAUDI ARABIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SPAIN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. SWEDEN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. SWITZERLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. TURKEY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED ARAB EMIRATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. METABOLIC DISORDERS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 103. METABOLIC DISORDERS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023